BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 14652986)

  • 21. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy for invasive aspergillosis.
    Viscoli C
    Clin Infect Dis; 2004 Sep; 39(6):803-5. PubMed ID: 15472811
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
    Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
    J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination antifungal therapy for invasive aspergillosis.
    Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
    Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
    Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
    Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacies and clinical roles of new antifungal agents].
    Tokimatsu I; Kadota J
    Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
    Klastersky J
    N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
    [No Abstract]   [Full Text] [Related]  

  • 29. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
    Clemons KV; Parmar R; Martinez M; Stevens DA
    J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
    Pagano L; Valentini CG; Fianchi L; Caira M
    J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 34. [Invasive aspergillosis: clinical manifestations and treatment].
    Lumbreras C; Gavaldá J
    Rev Iberoam Micol; 2003 Sep; 20(3):79-89. PubMed ID: 15456363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
    Chandrasekar PH; Cutright JL; Manavathu EK
    Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disseminated invasive aspergillosis in a patient with acute leukaemia.
    Gottfredsson M; Steingrímsdóttir H
    Acta Biomed; 2006; 77 Suppl 2():10-3. PubMed ID: 16918060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systemic antifungal agents].
    Lumbreras C; Lizasoain M; Aguado JM
    Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
    Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin.
    Alanio A; Brethon B; Feuilhade de Chauvin M; de Kerviler E; Leblanc T; Lacroix C; Baruchel A; Menotti J
    Clin Infect Dis; 2008 May; 46(10):e116-8. PubMed ID: 18419477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.